Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.…
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics (NASDAQ: DSGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 9.020 USD on 20 November 2026, up 19.3% over 52 weeks. Its 52-week range is 6.680 USD to 17.25 USD: the price is 47.7% below the high and 35.0% above the low.
Its market capitalisation is 577.61M USD.
Design Therapeutics reports return on equity of -32.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 206.09M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.57 USD is 139.2% above the current price. The next earnings report is expected on 9 March 2027.